|
Has Colorectal Cancer (c-)Met Its Match With Telisotuzumab Adizutecan?
May 27, 2026 Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors May 27, 2026 Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? May 27, 2026 Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making? May 27, 2026 Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial May 27, 2026 Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors May 27, 2026 Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors May 27, 2026 Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma May 27, 2026 Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials May 27, 2026 Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19 May 27, 2026 Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study May 27, 2026 Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation May 27, 2026 From Darkness to Light May 27, 2026 Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology May 27, 2026 Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer” May 27, 2026 Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer May 27, 2026 Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer” May 27, 2026 Key Methodological Considerations in the Interpretation of the CONKO-007 Trial May 27, 2026 Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer” May 27, 2026 Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer” May 27, 2026 Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer May 27, 2026 Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial May 27, 2026 Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial May 27, 2026 Erratum: Indistinguishable From Magic May 27, 2026 Indistinguishable From Magic May 27, 2026 Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors May 27, 2026 Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors May 27, 2026 |
From Darkness to Light Journal of Clinical Oncology, Volume 44, Issue 20, Page 1945-1946, July 2026. <br/> 2026-07-10T07:00:00Z Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study Journal of Clinical Oncology, Volume 44, Issue 20, Page 1921-1932, July 2026. <br/> 2026-07-10T07:00:00Z Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma Journal of Clinical Oncology, Volume 44, Issue 20, Page 1889-1898, July 2026. <br/> 2026-07-10T07:00:00Z Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials Journal of Clinical Oncology, Volume 44, Issue 20, Page 1899-1910, July 2026. <br/> 2026-07-10T07:00:00Z Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19 Journal of Clinical Oncology, Volume 44, Issue 20, Page 1911-1920, July 2026. <br/> 2026-07-10T07:00:00Z Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors Journal of Clinical Oncology, Volume 44, Issue 20, Page 1876-1888, July 2026. <br/> 2026-07-10T07:00:00Z Perioperative Toripalimab Plus Chemotherapy Versus Chemotherapy Alone in Locally Advanced Gastric or Gastroesophageal Junction Cancer: 3-Year Follow-Up of NEOSUMMIT-01 Trial Journal of Clinical Oncology, Volume 44, Issue 20, Page 1869-1875, July 2026. <br/> 2026-07-10T07:00:00Z Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation Journal of Clinical Oncology, Volume 44, Issue 20, Page 1933-1944, July 2026. <br/> 2026-07-10T07:00:00Z Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems? Journal of Clinical Oncology, Volume 44, Issue 20, Page 1860-1864, July 2026. <br/> 2026-07-10T07:00:00Z Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making? Journal of Clinical Oncology, Volume 44, Issue 20, Page 1865-1868, July 2026. <br/> 2026-07-10T07:00:00Z Key Methodological Considerations in the Interpretation of the CONKO-007 Trial Journal of Clinical Oncology, Volume 44, Issue 20, Page 1950-1951, July 2026. <br/> 2026-07-10T07:00:00Z Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer Journal of Clinical Oncology, Volume 44, Issue 20, Page 1949-1950, July 2026. <br/> 2026-07-10T07:00:00Z Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology Journal of Clinical Oncology, Volume 44, Issue 20, Page 1947-1949, July 2026. <br/> 2026-07-10T07:00:00Z Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial Journal of Clinical Oncology, Volume 44, Issue 20, Page 1955-1955, July 2026. <br/> 2026-07-10T07:00:00Z Erratum: Indistinguishable From Magic Journal of Clinical Oncology, Volume 44, Issue 20, Page 1955-1955, July 2026. <br/> 2026-07-10T07:00:00Z Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors Journal of Clinical Oncology, Volume 44, Issue 20, Page 1956-1956, July 2026. <br/> 2026-07-10T07:00:00Z |
Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression
A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. 2026-07-10
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. 2026-07-09
For Those Left Behind An ICU physician believed letting her father die at home meant comfort, dignity, control, family close by, and the quiet reassurance of hospice. But she didn’t realize what it would require of her family. 2026-07-09
Condyloma Acuminata of the Urethra A 42-year-old man with a recent stem-cell transplant presented with a 2-week history of urinary frequency and weak stream. Papules were seen on the penile shaft. Urethroscopy showed papillomatous lesions on the urethral mucosa. 2026-07-09
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but an increased risk of grade 3 or higher adverse events. 2026-07-02
The Invisible Load of Cognitive Symptoms Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them? 2026-07-02
Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. 2026-06-25
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma. 2026-06-25
TRACTION for Greater Surgical Use of Tranexamic Acid Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... 2026-06-25
When Health Costs No Longer Count — Air Pollution and EPA Rulemaking The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. 2026-06-25
Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing. 2026-06-25
Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. 2026-06-18
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding. 2026-06-18
Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. 2026-06-18
Management of Differentiated Thyroid Cancer This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. 2026-06-18
Case 17-2026: A 74-Year-Old Man with Pancytopenia A 74-year-old man with a recent orthotopic heart transplantation was admitted to the hospital because of persistent pancytopenia that resulted in serial transfusions of packed red cells. A diagnosis was made. 2026-06-18
Stenting for Post-Thrombotic Syndrome — A Step Forward Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... 2026-06-18
Prehospital Whole Blood for Traumatic Hemorrhage — Consistent Evidence from Two Randomized Trials Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and... 2026-06-18
Stemness as the Engine of Checkpoint Durability The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect. 2026-06-18
Immunosuppression-Associated Peripheral T-Cell Lymphoma A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate. 2026-06-18
|
|
|
| |||
|
[Editorial] Historic moments
Attending large scientific conferences can be an endurance test. The sunrise sessions, the multiple parallel tracks, the thousands of steps walking back-and-forth from one end of a convention centre to the other, and the evening receptions, all combined with meetings with colleagues, old and new. But occasionally, it becomes apparent that the conference in question is different, that something historic has happened. This year's American Society of Clinical Oncology (ASCO) annual meeting was one such occasion, evoking memories of other examples such as ASCO 2010 and the 2025 San Antonio Breast Cancer Symposium (SABCS). Wed, 01 Jul 2026 00:00:00 -0700
[Comment] SUBITO: validating biology, not intensity The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate surrounding high-dose chemotherapy with autologous stem-cell rescue in patients with high-risk early breast cancer, exploring its potential role in the modern era of therapies targeted to homologous recombination-deficient (HRD) tumours. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Customised radiation after neoadjuvant chemotherapy in breast cancer Although oestrogen receptor, progesterone receptor, and HER2 receptor expression status help to tailor neoadjuvant systemic therapy regimens in patients with breast cancer, the response to treatment is arguably more prognostic than is receptor status itself. The amount of residual disease following neoadjuvant therapy, as calculated by the residual cancer burden index, correlates with disease recurrence independent of stage or receptor status.1 In patients with high risk of recurrence based on substantial residual disease, trials such as KATHERINE and CREATE-X provide data to support escalation of adjuvant systemic therapy, providing truly personalised medicine for patients with breast cancer. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Preliminary results from PRIMARY2: bringing colour to a grey arena A non-invasive diagnostic test that enables us to safely avoid an invasive test is valuable. Historically, an elevated prostate-specific antigen (PSA) was the primary driver for a prostate biopsy. This approach was refined as a result of multiple large trials demonstrating the benefit of an MRI-based triage system, with MRI generally increasing the detection of clinically significant prostate cancer while reducing prostate biopsies.1 Wed, 10 Jun 2026 22:30:01 +0000
[Comment] Radiotherapy dose escalation in glioblastoma: the thin ice of of historical controls In The Lancet Oncology, Frank A Giordano and colleagues report the outcome of the INTRAGO II trial, a randomised, phase 3 study investigating the benefit of radiotherapy dose intensification in 314 patients with glioblastoma. The authors must be congratulated for successfully completing a technically complex trial. The radiotherapy boost was given with an additional 30 Gy single dose of intraoperative radiation by use of low-energy x-rays emitting 50 kV photons to the resection cavity, in addition to standard-of-care chemoradiotherapy. Wed, 01 Jul 2026 00:00:00 -0700
[Comment] Artificial intelligence volumetry in mesothelioma: ready for deployment? Pleural mesothelioma is an uncommon, asbestos-associated cancer. Unlike most primary tumours, which grow spherically, mesothelioma conforms to the complex shape of the pleural cavity. As the disease progresses, multifocal tumour nodules coalesce and thicken to produce a crescent-shaped rind encasing the lung. Tumour foci might invade into adjacent structures, with limited between-plane resolution on routine imaging. This morphological complexity, combined with a typical pleural surface area of around 4000 cm2, makes radiological quantification extremely challenging. Wed, 17 Jun 2026 22:30:04 +0000
[Comment] Delivering transformational change for patients and the environment through England's National Cancer Plan The National Cancer Plan for England, published in February, 2026, sets out ambitious plans for the future of cancer care in England over the next 10 years.1 Overlooked in the plan, however, is the need to align these plans with the legal commitment of the National Health Service (NHS) to developing an environmentally sustainable health-care system, reducing health care-associated greenhouse gas emissions to net zero by 2045.2 Many policies set out in the plan could contribute to achieving this goal—realising co-benefits for health and environment—but the potential environmental impacts of some proposals need careful evaluation before and during implementation. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] The intermediate-risk gap in AI-based breast cancer stratification Gil Shamai and colleagues1 have produced the most methodologically rigorous computational pathology model to date for recurrence-score estimation in hormone receptor-positive, HER2 (also known as ERBB2)-negative early breast cancer. Leveraging TAILORx randomised treatment assignments to show differential chemotherapy benefit by menopausal status—a distinction no previous computational pathology study has achieved—the model raises the bar for the field. The minimal calibration approach, requiring only 100 slides and no local genomic labels, addresses barriers to deployment in resource-limited settings. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] The intermediate-risk gap in AI-based breast cancer stratification – Authors' reply We thank Koinis and colleagues for raising a concern worth clarifying, as other readers might share it. They describe the intermediate-risk population as the group in which stratification is most needed, and argue that our model adds little value there. This conflates two distinct concepts: intermediate clinical or genomic risk and intermediate artificial intelligence (AI) risk. Our AI model is, itself, a stratification tool that resolves subpopulations within the conventionally uncertain clinical and genomic groups, precisely where it is most needed. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Terbium-161 might be superior to lutetium-177 for oligometastases Bastiaan M Privé and colleagues reported on the phase 2 trial BULLSEYE, which investigated prostate-specific membrane antigen (PSMA) radioligand therapy with [177Lu]Lu-prostate-specific membrane antigen-617 ([177Lu]Lu-PSMA-617) in patients with PSMA-expressing oligometastatic (≤5 metastases) hormone-sensitive prostate cancer (HSPC), in a setting of biochemically recurrent prostate cancer with a fast prostate-specific antigen (PSA) doubling time of less than 6 months.1 Patients were randomly assigned to 177Lu-PSMA-617 every 6 weeks for up to four cycles or to deferred androgen deprivation therapy (ADT) with active monitoring. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Terbium-161 might be superior to lutetium-177 for oligometastases – Authors' reply We thank Elif Hindié and colleagues for their thoughtful comments on our recent Article.1 Interest in higher linear energy transfer (LET) radiopharmaceuticals, such as terbium-161 (161Tb), has recently increased.2 161Tb resembles lutetium-177 (177Lu) in its decay but additionally emits low-energy conversion electrons and Auger electrons with high LET. These electrons could induce greater genotoxicity at the cellular level,3 raising the hypothesis that micrometastases could be more effectively treated, similar to proposed advantages of alpha-emitters. Wed, 01 Jul 2026 00:00:00 -0700
[Correspondence] Chemotherapy ports and the overlooked infrastructure of cancer care We write as clinicians and cancer survivors who underwent prolonged chemotherapy for oesophageal cancer. Our experiences highlight how access to implantable venous access devices (chemotherapy ports) can shape treatment quality, adherence, and dignity. Although standard in high-income settings, these devices remain unavailable or unaffordable in low-income and middle-income countries (LMICs), revealing an overlooked inequity in cancer care infrastructure. Wed, 01 Jul 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2025; 26: e369–80 Al-Thani MBH, Subramanian M, Halabi N, et al. Qatar national cancer care and research: pioneering strategies for global health excellence. Lancet Oncol 2025; 26: e369–80—In this Series paper, the labels for figure 2A have been corrected so that Qatar is the red line and the USA is the blue line. These corrections have been made to the online version as of June 29, 2026. Wed, 01 Jul 2026 00:00:00 -0700
[News] PMI faces questions over cigarette marketing and smoke-free commitments Over the past 10 years, Philip Morris International (PMI; headquartered at Stamford, CT, USA), a tobacco company, has repeatedly stated its intention to deliver a smoke-free future. According to the PMI website, it is “actively accelerating the decline of cigarette smoking beyond what traditional tobacco control measures can achieve alone.” Nonetheless, a new international advertising drive featuring PMI's flagship brand Marlboro has prompted critics to question the company's commitment to ending sales of combustible cigarettes. Fri, 29 May 2026 22:30:02 +0000
[News] Spain expands breast cancer screening programme The Public Health Commission in Spain has approved the expansion of the national breast cancer screening programme to include women aged 45–74 years. Fri, 29 May 2026 22:30:02 +0000
[News] Cancer screening expands as implementation gaps remain On May 26, 2026, the European Cancer Organisation published the European Cancer Screening Policy Index 2026; on May 27, 2026, the American Cancer Society updated its colorectal cancer screening guidance to include blood-based testing for some adults; and Indonesia added colorectal cancer screening to its National Free Health Checkup programme for people aged 45 years and older who are at high risk. These developments come as health systems are under pressure not only to detect cancer earlier, but to ensure that screening is organised, equitable, and followed by diagnosis and care. Thu, 04 Jun 2026 22:30:01 +0000
[News] 2026 ASCO Annual Meeting To a standing ovation in the Plenary Session, Brian Wolpin (Dana-Farber Cancer Institute, Boston, MA, USA) on behalf of an international team of researchers presented remarkable data from the RASolute 302 phase 3 trial, which showed a doubling of overall survival for patients with metastatic pancreatic adenocarcinoma. Pancreatic cancer is notoriously difficult to treat, but oncogenic RAS mutations are typically seen in more than 90% of cases, offering a unique opportunity for therapy. Daraxonrasib is a new oral, RAS(ON) multiselective, tri-complex inhibitor of mutant and wild type RAS. Thu, 04 Jun 2026 22:30:00 +0000
[News] French MPs vote for sharp cuts in cadmium content in fertilisers The French National Assembly, or the lower house of Parliament, has adopted a private member's bill on a first reading to scale down the amount of cancer-causing cadmium used in phosphate fertilisers in France, from 90 mg/kg to 20 mg/kg by 2030. Thu, 11 Jun 2026 22:30:01 +0000
[News] UK prostate cancer screening trial to include more Black men The UK Government has pledged £20 million to help improve prostate cancer research and treatment, including the expansion of a landmark screening trial to include all Black men who are eligible. Thu, 11 Jun 2026 22:30:01 +0000
[News] Almost a third of Americans set to live in jurisdictions allowing assisted dying Campaigners say the USA will reach a “monumental” juncture in September, 2026, when a total of 14 jurisdictions will legally allow medical aid in dying (MAID) after laws in the states of New York and Illinois come into force. Thu, 18 Jun 2026 22:30:02 +0000
[News] India's cancer drugs shortages mitigated through price increase The price of platinum-based cancer drugs in India has been raised in response to a nationwide shortage, following Government approval last week. Thu, 18 Jun 2026 22:30:02 +0000
[Perspectives] Should regional nodal irradiation be omitted in patients with node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy? *Sachin R Jhawar, Jose G BazanDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43212, USA (SRJ); Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA (JGB) Wed, 01 Jul 2026 00:00:00 -0700
[Perspectives] OncoCorridor: connecting patients with cancer in conflict zones to treatment centres worldwide Over 2 billion people currently reside in conflict-affected areas. For millions of people affected by cancer in these areas, disruptions in health services lead to treatment delays or interruptions and, ultimately, amenable deaths. That people should endure both conflict and avoidable cancer death is a double injustice our professional oaths oblige us to confront. The OncoCorridor initiative, led by OncoDaily and the Institute of Cancer and Crisis, aims to reduce avoidable deaths from people diagnosed with cancer in conflict-affected regions by establishing a global network that connects them with treatment centres worldwide. Mon, 18 May 2026 13:00:01 +0000
[Articles] Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial Aumolertinib in combination with chemotherapy significantly improved progression-free survival. Although this regimen was associated with increased toxicity, the side-effects were managed with dose adjustment and supportive treatment aligned with clinical practice. Long-term follow-up is required to assess overall survival. The AENEAS2 study provides evidence to guide clinical practice regarding EGFR-TKIs and their combination use in treating patients with advanced EGFR-mutated NSCLC. Tue, 16 Jun 2026 09:52:47 +0000
[Articles] Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Tailoring radiotherapy in cT1–2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study Tailoring locoregional radiotherapy in cT1–2N1 breast cancer (with ≤3 nodes at imaging) to the nodal response after primary systemic therapy resulted in a low 10-year locoregional recurrence rate, with promising recurrence-free interval and overall survival. By (partially) omitting radiotherapy based on nodal response after primary systemic treatment, possible morbidity caused by the radiotherapy can be avoided, which could improve patients’ quality of life. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer Breast cancer mortality at 20 years was significantly lower in the IM-MS irradiation group, whereas non-breast cancer mortality was numerically higher in the IM-MS irradiation group after 15 years, resulting in no long-term benefit of IM-MS irradiation on overall survival. Our results emphasise the importance of very long-term follow-up and advanced irradiation techniques to reduce the dose to organs of interest. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial [68Ga]Ga-PSMA-11 PET-CT could have the potential to improve the diagnostic pathway of patients with a high clinical risk but non-suspicious or equivocal prostate MRI. Further research, including health-economic analyses and validation with other PSMA radiopharmaceuticals, are needed to confirm the clinical implementation and generalisability of this approach. Wed, 10 Jun 2026 22:30:01 +0000
[Articles] Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial Perioperative systemic therapy cannot be recommended in all patients with resectable colorectal peritoneal-only metastases. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial Instant, spatially precise dose escalation with intraoperative radiotherapy added to standard of care did not improve outcomes, questioning the value of further local dose intensification in resectable glioblastoma. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study ARTIMES-based progression-free survival improves prognostic stratification and shows better trial-level surrogacy for overall survival compared with mRECIST-based progression-free survival. Pending prospective validation, ARTIMES could potentially facilitate a more reliable response evaluation in pleural mesothelioma. Wed, 17 Jun 2026 22:30:05 +0000
[Articles] Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials The toxicity profile of T cell-engaging bispecific antibodies varies substantially across cancer types and antibody classes. This meta-analysis provides a comprehensive overview of treatment-related adverse event incidence and patterns, offering a valuable reference for optimising patient management in clinical practice. Fri, 12 Jun 2026 22:30:01 +0000
[Review] Novel strategies to overcome the blood–brain barrier in triple-negative breast cancer brain metastases Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood–brain barrier, long viewed as an impermeable therapeutic sanctuary, is the core barrier to effective care. This Review advocates a key paradigm shift for clinical and translational research: from merely circumventing the blood–brain barrier to actively targeting and exploiting its biology. We delineate triple-negative breast cancer-specific mechanisms of blood–brain barrier breach and evaluate emerging therapies via a clinically actionable three-pillar framework: physical and focal blood–brain barrier disruption, biological blood–brain barrier exploitation, and microenvironmental modulation. Wed, 01 Jul 2026 00:00:00 -0700
[Policy Review] European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine Imaging is central to diagnosing, staging, evaluating treatment response, and guiding post-therapy surveillance in osteosarcoma and Ewing sarcoma, yet no international consensus defines optimal modalities or schedules. This European guideline, developed by 36 multidisciplinary experts, seeks to standardise imaging for research and enhance patient care. A systematic review identified 2026 studies, of which 13 met criteria, revealing marked heterogeneity in diagnoses, chemotherapy regimens, and imaging protocols. Wed, 01 Jul 2026 00:00:00 -0700
[Policy Review] Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options. The increasing use of modern conformal radiotherapy techniques, including intensity-modulated radiotherapy, proton therapy, and stereotactic body radiotherapy, has expanded the feasibility of reirradiation in clinical practice. However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk. Wed, 01 Jul 2026 00:00:00 -0700
|
Analysis of a large osteosarcoma sequencing data set elucidates patterns of genomic alterations
Novel findings from this statistically rigorous analysis of a large patient population include: identifying genes of interest in osteosarcoma that are more often altered when compared to other cancers; identifying MYC and CCND3 amplification as significantly more prevalent in osteosarcoma diagnosed in childhood; and proving mutual exclusivity and co‐occurrence with statistical robustness. Thu, 09 Jul 2026 08:41:12 -0700 The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer‐related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial Neighborhood socioeconomic disadvantage may contribute to cognitive vulnerability before cancer treatment. However, these findings suggest that years of education and depressive symptoms should be factored into the consideration of neighborhood‐level factors when assessing CRCI risk among women with breast cancer (Clinicaltrials.gov identifier NCT02793921). Thu, 09 Jul 2026 01:25:10 -0700 Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps Thu, 09 Jul 2026 01:17:43 -0700 Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre‐immunotherapy era, and should be used when no other options are available. Tue, 07 Jul 2026 03:51:08 -0700 Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma Tue, 07 Jul 2026 03:33:53 -0700 Bendamustine in indolent lymphoma: Letting the dust settle down Tue, 07 Jul 2026 03:31:51 -0700 Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality Tue, 07 Jul 2026 03:16:02 -0700 Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States Disparities in cervical and breast cancer screening persist among SOGI minorities. These findings underscore prevalent structural and systemic barriers in preventive cancer care and highlight the need for inclusive, culturally sensitive interventions to promote equitable screening access. Mon, 06 Jul 2026 00:01:06 -0700 Toward exercise as standard care for older cancer survivors Fri, 03 Jul 2026 10:29:49 -0700 Maintenance therapy in gynecologic malignancies: Current and future state Fri, 03 Jul 2026 10:19:52 -0700 Long‐term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970–1999: A report from the Childhood Cancer Survivor Study No differences in late mortality, SMNs, and most CHCs were observed between patients who received VDC versus VDC/IE. Aging EWS survivors’ elevated risk of morbidity and mortality underscores the need for lifelong survivorship care and therapies that reduce the risk for late effects. Thu, 02 Jul 2026 08:40:00 -0700 Large‐scale osteosarcoma sequencing reveals age‐associated genomic architectures Thu, 02 Jul 2026 08:15:32 -0700 Issue Information Thu, 02 Jul 2026 00:00:00 -0700 |
||
|
| |||
|
[Editorial] Ebola outbreak: why haematology matters
As of June 3, WHO Director-General Tedros Ghebreyesus reported 344 confirmed cases of Ebola virus disease in DR Congo, as well as 15 confirmed cases in Uganda. Encouragingly, suspected cases in the DR Congo have fallen, as efforts continue to eliminate delays in testing. However, this outbreak, caused by Bundibugyo virus (Orthoebolavirus bundibugyoense), highlights a recurring vulnerability in epidemic preparedness: limited access to reliable and accurate diagnostics and absence of specific treatments and vaccines. Wed, 10 Jun 2026 22:30:01 +0000
[Comment] Apixaban for paediatric venous thromboembolism: cautious optimism For decades, paediatric anticoagulation has been guided more by extrapolation than by evidence. Treatments for venous thromboembolism in children have largely mirrored adult practice, despite fundamental developmental differences in haemostasis and drug handling. The emergence of direct oral anticoagulants (DOACs) marks a turning point, with the first generation of trials specifically designed for paediatric populations published in the past 5 years. Within this context, the study by Leonardo R Brandão and colleagues1 provides timely and important data on apixaban in children with venous thromboembolism. Wed, 01 Jul 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; 13: e338–50 Edel Y, Stein PE, Kawtharany H, et al. Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network. Lancet Haematol 2026; 13: e338–50—In this Review, the list of countries in the first paragraph of the Methods section should contain Norway and not Denmark. This change has been made on May 27, 2026. Wed, 27 May 2026 22:30:01 +0000
[Corrections] Correction to Lancet Haematol 2026; 13: e396–407 Donzel M, Khedimallah S, Barriere S, et al. Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study. Lancet Haematol 2026; 13: e396–407—In this Article, Agathe Gouband and Damien Luque Paz's affiliation should have been “Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France”, and their degrees should have been PharmD. In addition, the acknowledgments should read “We thank the FIMBANK network, funded by the French Institut National du Cancer (INCa BCB 2013 & 2022), for providing data for some of the patients included in the present study.” These corrections have been made to the online version as of July 2, 2026. Wed, 01 Jul 2026 00:00:00 -0700
[In Focus] Essential but neglected: securing the global supply of human hyperimmune immunoglobulins In 2025, the European Medicines Agency and the Heads of Medicines Agencies issued recommendations to address vulnerabilities in the supply of anti-RhD immunoglobulin (RHIG; used to prevent RhD alloimmunisation during pregnancy). This alert highlights a broader but under-recognised problem: the fragile global supply of hyperimmune immunoglobulins, a group of plasma-derived medicines essential for post-exposure prophylaxis (PEP) and maternal–child health. Despite their various inclusions in the WHO Model Lists of Essential Medicines for adults and children and in national lists, these products remain vulnerable to shortages and fragmented procurement in both high-income countries (HICs) and low-income and middle-income countries (LMICs). Wed, 01 Jul 2026 00:00:00 -0700
[In Focus] Exhibition: sharing the history of blood through patients’ stories With its museums, art galleries, and a castle that dominates the skyline, it is little wonder that Edinburgh, UK, is ranked regularly among the most popular global destinations for tourists. Yet if visitors look beyond the most famous attractions—such as the Palace of Holyroodhouse, the Royal Yacht Britannia, and the Royal Botanic Garden—then Scotland's capital city boasts a plethora of destinations that lie off the beaten track. One of those hidden gems is the Physicians’ Gallery on Queen Street, a free museum in which the Royal College of Physicians of Edinburgh (RCPE) hosts exhibitions drawn from its library of more than 85 000 books, journals, pamphlets, and other items, supplemented with exhibits borrowed from other collections. Wed, 01 Jul 2026 00:00:00 -0700
[Articles] Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted. Fri, 12 Jun 2026 22:30:01 +0000
[Articles] Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths. Tue, 16 Jun 2026 09:52:41 +0000
[Articles] Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study Our findings could assist clinicians in delivering more targeted and timely supportive care interventions and might inform patients about anticipated symptoms during the early post-CAR T-cell infusion period. Moreover, the observed discrepancies between patient-reported and clinician-reported symptoms suggest that more systematic use of patient-reported outcome measures might provide complementary insights beyond those captured through clinician assessment. Fri, 12 Jun 2026 22:30:01 +0000
[Articles] Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial In this descriptive study, the safety and efficacy profile of a fixed-dose-by-bodyweight-tier apixaban regimen was similar to that of standard of care for the treatment of venous thromboembolism and prevention of venous thromboembolism recurrence in children younger than 18 years, providing a potential additional treatment option in this patient population. Wed, 01 Jul 2026 00:00:00 -0700
[Review] Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party The European Group for Blood and Bone Marrow transplantation Practice Harmonization and Guidelines Committee together with the Lymphoma Working Party convened 23 experts in Hodgkin lymphoma, transplantation, and radiation oncology, to develop consensus recommendations on the use of autologous and allogeneic haematopoietic cell transplantation (HCT) in relapsed or refractory Hodgkin lymphoma. Through a structured literature review and a 2-day workshop in Berlin, Germany, on Sept 29 and 30, 2025, the panel established guidance across major clinical decision points. Wed, 01 Jul 2026 00:00:00 -0700
[Review] Female reproductive health—what the classical haematologist needs to know Haematologists should be prepared to address several key transitions and timepoints during the female reproductive health lifespan to provide safe and equitable care for all patients with haematological disorders. In this Review, we summarise important points for recognition and consideration in the care of patients with lifelong or transient haematological conditions. We include discussions on menarche, pregnancy, menopause, and gender-affirming care, and how these life transitions might impact people with underlying haematological disorders, including an increased risk of iron deficiency with or without anaemia. Tue, 16 Jun 2026 22:30:02 +0000
[Viewpoint] A US perspective on optimising the inpatient classical haematology consultation service The inpatient classical haematology consult service occupies a specialised, complex, and high-acuity domain in the hospital setting. As three academic classical haematologists practicing primarily or exclusively as inpatient consultants in the US, we describe the wide spectrum of haematological disorders we manage in our practices and the rapidly expanding number and complexity of treatments we have to offer, therefore necessitating a substantial breadth and depth of diagnostic and therapeutic expertise to practice successfully in this setting. Wed, 01 Jul 2026 00:00:00 -0700
[Clinical Picture] Fulminant haemophagocytic lymphohistiocytosis revealing an unexpected bone marrow pathogen A 25-year-old construction worker with a history of marijuana and cocaine use presented with 3 months of weight loss, fever, night sweats, cough, and progressive dyspnoea. He was transferred to Hospital Alma Mater de Antioquia (Medellín, Colombia) on Nov 20, 2025, after developing haemodynamic instability and worsening hypoxaemia, despite treatment with broad-spectrum antibiotics. Imaging showed a left pleural effusion with lower-lobe atelectasis, generalised lymphadenopathy, and hepatosplenomegaly. Wed, 01 Jul 2026 00:00:00 -0700
|
A bone to pick with ferric carboxymaltose
Volume 148, Issue 1 July 2 2026 Genomics reboot for secondary myelofibrosis Volume 148, Issue 1 July 2 2026 EBV and immunodeficiency: the odd couple drawn to the brain Volume 148, Issue 1 July 2 2026 Is low a go for pediatric AML? Volume 148, Issue 1 July 2 2026 When the KAT’s away, vulnerability for AML comes out to play Volume 148, Issue 1 July 2 2026 A step toward streamlining HIT diagnosis Volume 148, Issue 1 July 2 2026 ELISA-negative HIT: antibody recognition and relevance Volume 148, Issue 1 July 2 2026 Identifying steroid-refractory aGVHD before it happens Volume 148, Issue 1 July 2 2026 Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia The use of IV iron in clinical practice has increased significantly in recent years. In this Plenary Paper, Wagner and colleagues demonstrate that ferric carboxymaltose (FCM) is associated with a higher risk of fractures than ferric derisomaltose and show that FCM impairs bone recovery in mouse models despite correction of anemia. Mechanistically, FCM preferentially accumulates in bone, suppresses collagen production and bone formation pathways, alters dentin matrix protein 1–integrin signaling, and sustains elevated fibroblast growth factor 23 levels, suggesting that its skeletal toxicity extends beyond the well-recognized effects of hypophosphatemia. These findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.
Volume 148, Issue 1 July 2 2026 Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant Hairy cell leukemia (HCL) and HCL variant (HCLv) are uncommon chronic B-cell neoplasms that share several clinical and pathological features but differ substantially in their molecular drivers, clinical course, and therapeutic approach. Zent and colleagues present consensus guidelines that offer clinicians an updated overview of current approaches to diagnosing and managing patients with HCL and HCLv, along with perspectives on emerging targeted therapies aimed at improving outcomes.
Volume 148, Issue 1 July 2 2026 Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis Mora and colleagues have improved the existing myelofibrosis secondary to polycythemia vera and essential thrombocythemia prognostic model (MYSEC-PM) for secondary myelofibrosis by incorporating molecular and cytogenetic data, creating the mutation-enhanced MYSEC-mPM and the karyotype- and mutation-enhanced MYSEC-kmPM. By analyzing 644 patients, they identified mutations in ASXL1, U2AF1, TP53, and SRSF2, as well as complex or monosomal karyotypes, as independent predictors of poor survival, significantly improving risk stratification beyond clinical factors alone. These updated models provide more precise survival prediction that may better guide transplant decisions, patient monitoring, and clinical trial design.
Volume 148, Issue 1 July 2 2026 Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study Kaulen and colleagues from the International Primary CNS Lymphoma (PCNSL) Collaborative Group (IPCG) developed the IPCG ID-PCNSL prognostic score for immunodeficiency-associated PCNSL, demonstrating its ability to stratify outcomes across patients with HIV infection, solid organ transplantation, or autoimmune disorders. Their analysis highlights the biological and clinical distinctiveness of Epstein-Barr virus–driven PCNSL in immunocompromised patients, while showing that survival remains poor for high-risk groups despite widespread use of immune restoration strategies and rituximab- and high-dose methotrexate–based therapies. The study establishes the IPCG ID-PCNSL score as a practical tool for risk-adapted treatment decisions.
Volume 148, Issue 1 July 2 2026 Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial Induction therapy for pediatric acute myeloid leukemia (AML) is highly intensive and carries significant risks of toxicity. Gao and colleagues report results from the phase 3 CALS III-AML18 trial, showing that low-dose induction chemotherapy with granulocyte colony-stimulating factor achieves remission rates and survival outcomes comparable to those with standard-dose induction therapy in children with AML. This low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings. Further validation of this chemotherapy deescalation regimen is needed for optimization of low-dose approaches.
Volume 148, Issue 1 July 2 2026 Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML Lysine acetyltransferases (KATs) are chromatin modifiers that facilitate transcriptional activation. Meyerhöfer and colleagues demonstrate that pharmacologic inhibition of the KAT activity of p300/CREBBP unexpectedly activates interferon-stimulated genes in acute myeloid leukemia (AML) cells by increasing p300/CREBBP occupancy at interferon-responsive regulatory elements and promoting STAT1-mediated transcription. This transcriptional rewiring sensitized AML cells to interferon alpha, increased apoptosis, and reduced leukemia burden in both in vitro and in vivo models. Further preclinical evaluation is needed to understand the translational implications of these findings.
Volume 148, Issue 1 July 2 2026 Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia One of the major challenges in heparin-induced thrombocytopenia (HIT) diagnosis is differentiating between pathogenic and nonpathogenic anti–heparin/platelet factor 4 (PF4) antibodies. Bissola and colleagues developed engineered single-chain variable fragment (scFv) inhibitors derived from a HIT-like monoclonal antibody to selectively target pathogenic heparin/PF4 antibody epitopes and improve diagnostic discrimination in HIT. The incorporation of these scFvs into enzyme immunoassays increased specificity and improved assay accuracy in a small patient cohort. Further analytical and clinical validation in larger cohorts is required before clinical implementation.
Volume 148, Issue 1 July 2 2026 Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia In this study, Zhou et al show that some platelet-activating anti–platelet factor 4 (PF4) antibodies in heparin-induced thrombocytopenia (HIT) are not detected by standard PF4/heparin enzyme-linked immunosorbent assays (ELISAs). These ELISA-negative antibodies can still strongly activate platelets through FcγRIIA-dependent mechanisms and contribute substantially to pathogenic activity, reflecting context-dependent antigen recognition of PF4 complexes. Although these findings highlight limitations of current immunoassays, ELISA-negative functional antibodies appear uncommon in routine practice, reinforcing the continued importance of integrating clinical scoring with both immunoassays and functional platelet activation testing.
Volume 148, Issue 1 July 2 2026 CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD Steroid-refractory acute graft-versus-host disease (aGvHD) remains a major clinical challenge after allogeneic hematopoietic stem cell transplantation. Pan and colleagues investigated biomarkers that identify patients with newly developed aGvHD destined to become steroid refractory. Expansion of activated CD28+ CD8+ effector-memory T (Tem) cells was associated with steroid-refractory disease and linked to a proinflammatory, STAT1-driven reduction in glucocorticoid receptor expression. They further show that JAK/STAT inhibition with ruxolitinib can reverse these changes and restore steroid sensitivity, suggesting a potential strategy for early or preemptive treatment of high-risk patients.
Volume 148, Issue 1 July 2 2026 Therapy-related AML with MECOM rearrangement, biallelic TP53 inactivation, and striking nuclear abnormalities Volume 148, Issue 1 July 2 2026 Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013-3022. Volume 148, Issue 1 July 2 2026 Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913. Volume 148, Issue 1 July 2 2026 |
Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta‐Thalassemia Trait
Tue, 07 Jul 2026 05:57:10 -0700 POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management Tue, 07 Jul 2026 05:24:07 -0700 EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion‐Dependent Thalassemia Mon, 06 Jul 2026 00:14:05 -0700 Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count Sun, 05 Jul 2026 23:24:51 -0700 High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1% Fri, 03 Jul 2026 23:11:06 -0700 Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children Fri, 03 Jul 2026 22:48:08 -0700 Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management Fri, 03 Jul 2026 21:09:53 -0700 Striking Bone Marrow Plasmacytosis Resulting From Visceral Leishmaniasis Fri, 03 Jul 2026 14:42:47 -0700 Massive Neutrophil Necrobiosis due to Colchicine Toxicity Fri, 03 Jul 2026 14:42:47 -0700 Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents Fri, 03 Jul 2026 14:42:47 -0700 Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? Fri, 03 Jul 2026 14:42:47 -0700 Issue Information Fri, 03 Jul 2026 14:42:47 -0700 Correction to “DNA Methylation Episignature as a Novel Diagnostic Tool for Diamond‐Blackfan Anemia Syndrome” Fri, 03 Jul 2026 14:42:47 -0700 The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation Fri, 03 Jul 2026 14:42:47 -0700 CAR T‐Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study Fri, 03 Jul 2026 14:42:47 -0700 Response to: “Refining Combined‐Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma” Fri, 03 Jul 2026 14:42:47 -0700 Response to: “Refining Combined‐Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma” Fri, 03 Jul 2026 14:42:47 -0700 Hydroxyurea Delays the Onset of Hyposplenism in Young Children With Sickle Cell Disease Fri, 03 Jul 2026 14:42:47 -0700 Common Threshold of Measurable Disease Improperly Excludes Patients With AL Amyloidosis From Clinical Trials Fri, 03 Jul 2026 14:42:47 -0700 Response to Methodological Concerns Regarding Eligibility Criteria and Study Selection in a Systematic Review and Meta‐Analysis of CAR T‐Cell Therapy for Hematologic Malignancies Fri, 03 Jul 2026 14:42:47 -0700 NGS‐Driven Digital PCR for Personalized and Accurate Measurable Residual Disease Assessment in Acute Myeloid Leukemia Fri, 03 Jul 2026 14:42:47 -0700 |
|
|
| |||
|
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity
New England Journal of Medicine, Volume 395, Issue 2, Page 138-150, July 9, 2026.
Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer New England Journal of Medicine, Volume 395, Issue 2, Page 151-161, July 9, 2026.
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Volume 395, Issue 2, Page 115-126, July 9, 2026.
Nutrition Therapy in Critically Ill Adults New England Journal of Medicine, Volume 395, Issue 2, Page 162-174, July 9, 2026.
Immediate or Deferred Nonculprit-Lesion PCI New England Journal of Medicine, Volume 395, Issue 2, Page 205-206, July 9, 2026.
Trends and Prevalence of Chronic Kidney Disease in the United States New England Journal of Medicine, Volume 395, Issue 2, Page 201-203, July 9, 2026.
Contextualizing the Dead Donor Rule in an Era of Voluntary Euthanasia New England Journal of Medicine, Volume 395, Issue 2, Page 194-200, July 9, 2026.
The OMB and the Politicization of Science New England Journal of Medicine, Volume 395, Issue 2, Page 187-188, July 9, 2026.
Sparganosis New England Journal of Medicine, Volume 395, Issue 2, July 9, 2026.
Case 19-2026: A 68-Year-Old Man with Fatigue, Fever, and Hypoxemia New England Journal of Medicine, Volume 395, Issue 2, Page 176-185, July 9, 2026.
Mandated State-Level Surveillance of Assisted Reproductive Technology — An Emerging Threat in the United States New England Journal of Medicine, Volume 395, Issue 2, Page 110-112, July 9, 2026.
Caring for an Aging America — The Looming Crisis of the Long-Term–Care Workforce New England Journal of Medicine, Volume 395, Issue 2, Page 107-110, July 9, 2026.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer New England Journal of Medicine, Ahead of Print.
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer New England Journal of Medicine, Ahead of Print.
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer New England Journal of Medicine, Ahead of Print.
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica New England Journal of Medicine, Ahead of Print.
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy New England Journal of Medicine, Ahead of Print.
Conservative Oxygen for Unresponsive Patients after Cardiac Arrest New England Journal of Medicine, Ahead of Print.
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease New England Journal of Medicine, Ahead of Print.
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema New England Journal of Medicine, Ahead of Print.
Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection New England Journal of Medicine, Ahead of Print.
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Ahead of Print.
Bundibugyo Virus Disease in 2026 — Clinical and Public Health Responses New England Journal of Medicine, Ahead of Print.
Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026 New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
A Watershed Moment in the Perioperative Treatment of Prostate Cancer New England Journal of Medicine, Ahead of Print.
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. New England Journal of Medicine, Ahead of Print.
The Social Contract of Bundibugyo Ebola Isolation New England Journal of Medicine, Ahead of Print.
|
||
|
| |||
|
|
|||
|
| |||
|
Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy
Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, according to study findings published in Immunity. Wednesday, June 17, 2026 11:45 AM AI-Powered Tumor Microenvironment Analysis May Predict Immunotherapy Response in Patients With Rare Cancers Analysis of the tumor microenvironment before and during treatment with the help of artificial intelligence (AI) may aid in predicting response to pembrolizumab in patients with rare cancers, according to findings of a study published in the Journal for ImmunoTherapy of Cancer. Monday, July 6, 2026 1:00 PM Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States A new study led by scientists from the International Agency for Research on Cancer (IARC) compared the performance of lung cancer risk prediction models against the criteria currently used to determine eligibility for lung cancer screening in the United States. Reseatchers found that all the... Monday, July 6, 2026 11:06 AM Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer. Rather than simply showing increased activation of classical invasive pathways, tumors from patients with obesity... Monday, July 6, 2026 10:47 AM Study Clarifies HPV-Related Cancer Risk in Immunosuppressed Populations As reported in JAMA Network Open by Meglic et al, a Swedish nested case-control study of immunosuppressed populations found that both people with human immunodeficiency virus (HIV) and solid organ transplant recipients had increased odds of human papillomavirus (HPV)–related cancers, although the... Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy In a meta-analysis reported in JAMA Oncology, Tomasik et al found that second primary malignant neoplasms were a “clinically relevant complication” of treatment with T-cell–engaging bispecific antibodies (BsAbs) in patients with non-Hodgkin lymphoma or multiple myeloma. Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans In a study reported in The Lancet Oncology, Kirby et al identified real-world heart and lung radiation doses associated with English National Health Service (NHS) radiotherapy treatment plans in breast radiotherapy practices. Previously Untreated Advanced NSCLC With High PD-L1 Expression: PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy? In a meta-analysis reported in JAMA Oncology, Di Federico et al found that the addition of first-line platinum-based chemotherapy to PD-1/-L1 inhibition was associated with improved outcomes in patients with advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression. Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research... Thursday, July 2, 2026 10:00 AM AACR Statement and Call to Action Concerning OMB Proposal On June 30, the American Association for Cancer Research (AACR) issued the following statement: Thursday, July 2, 2026 10:00 AM Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or... Wednesday, June 24, 2026 1:00 PM Single-Fraction SBRT in Localized Prostate Cancer In a phase I/II trial reported in JAMA Oncology, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse–free survival rate in patients with localized prostate cancer. Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,... FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative... Wednesday, July 1, 2026 11:08 AM Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated stereotactic ablative body radiotherapy (SABR) in patients with primary renal cell carcinoma... FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic... Friday, June 12, 2026 4:47 PM ASCO Remembers Karnofsky Award Recipient Maura L. Gillison, MD, PhD, Pioneer in HPV-Associated Cancers Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs A novel bleeding risk score provides clinically relevant stratification for major bleeding risk in patients with cancer-associated venous thromboembolism (VTE) who received direct oral anticoagulant (DOAC) therapy, according to findings published in JACC: CardioOncology. Tuesday, June 30, 2026 11:00 AM Long-Term Outcomes With SABR in Primary Kidney Cancer As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ablative body radiotherapy (SABR) in patients with primary kidney cancer who did not undergo... MRI-Guided Radiotherapy in High-Grade Glioma In a single-center Canadian phase II trial (UNITED) reported in The Lancet Oncology, Detsky et al found that magnetic resonance imaging (MRI)-guided adaptation of radiotherapy allowed margin de-escalation and resulted in a low rate of marginal failure in patients with high-grade glioma. I Miss My Life AACR Cancer Disparities Progress Report: Mortality Rates Improve, But Care Inequities Persist The American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026 on June 24. The report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since 1991, translating to... Fertility Preservation Access Remains ‘Limited and Unequal’ for Many Girls and Young Women With Cancer A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer. Monday, June 29, 2026 11:13 AM Adverse Events With CD3-Based T-Cell–Engaging Bispecific Antibody Treatment in Cancer In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers. Survey Results Show Patients Prefer Learning of a Diagnosis From Their Doctor Rather Than a Health Portal Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a... Monday, June 29, 2026 11:45 AM Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the... Wednesday, June 24, 2026 2:00 PM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
CRISPR–Cas technologies provide a modular, programmable platform for sequence-specific targeting of DNA or RNA and have advanced from experimental molecular biology tools to clinical translation. This Review describes current and emerging applications of CRISPR–Cas platforms in oncology, including their use in discovery research, diagnostics and therapeutics. Thu, 09 Jul 2026 00:00:00 -0700 Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer Perioperative chemoimmunotherapy, comprising platinum-doublet chemotherapy plus an anti-PD-(L)1 antibody, has become the standard-of-care approach for patients with resectable non-small-cell lung cancer without an actionable driver alteration. However, the development of this approach has thus far been largely empirical, with limited capacity for adaptation of treatment strategies to better meet the needs of individual patients. In this Review, the authors discuss the potential for improvements in the current approach to perioperative therapy, including de-escalation for those with a pathological complete response, the capacity of various baseline and/or dynamic biomarkers to optimize outcomes, and the potential for escalation in patients with early evidence of a lack of responsiveness in the perioperative setting. Tue, 30 Jun 2026 00:00:00 -0700 Patient value over patent value: the mandate for open-source oncology Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership. Fri, 26 Jun 2026 00:00:00 -0700 Cancer burden and control in China: landscape, trends and challenges Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets. Fri, 19 Jun 2026 00:00:00 -0700 New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose. Wed, 17 Jun 2026 00:00:00 -0700 Antibody–drug conjugates in gynaecological cancers: opportunities and challenges Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities. Wed, 17 Jun 2026 00:00:00 -0700 Teclistamab monotherapy improves survival in RRMM Teclistamab monotherapy improves survival in RRMM Mon, 15 Jun 2026 00:00:00 -0700 Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia Fri, 12 Jun 2026 00:00:00 -0700 |
|
|
| |||
|
Development of a prognostic prediction model incorporating KDM1B for esophageal squamous cell carcinoma: an integrated transcriptomic and functional analysis
Vol 17, No 3 (June 29, 2026): Early palliative care decision is associated with reduced end-of-life healthcare utilization in patients with esophageal and gastric cancer Vol 17, No 3 (June 29, 2026): Machine learning-based gastric cancer risk prediction in an asymptomatic screening population: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Overexpression of TAZ is associated with downregulation of E-cadherin and indicates poor prognosis in gastric cancer: a clinicopathological study Vol 17, No 3 (June 29, 2026): Evaluating the prognostic value of cuproptosis-related genes and characterizing PDE3B’s role in gastric cancer: integrative bioinformatics analysis and experimental validation Vol 17, No 3 (June 29, 2026): p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells Vol 17, No 3 (June 29, 2026): Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas Vol 17, No 3 (June 29, 2026): Comparison of endoscopic submucosal dissection and surgery for early signet-ring cell carcinoma of the stomach: a multicenter study Vol 17, No 3 (June 29, 2026): Metabolic profile alterations as early indicators of gastrointestinal stromal tumors (GISTs) recurrence and imatinib resistance Vol 17, No 3 (June 29, 2026): A nomogram for predicting progression-free survival in stage III–IV gastric cancer based on post-treatment cholinesterase and C-reactive protein Vol 17, No 3 (June 29, 2026): Efficacy and safety of modified FLOT chemotherapy in gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Excess late mortality among long-term gastric cancer survivors following gastrectomy: a population-based cohort study Vol 17, No 3 (June 29, 2026): Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids Vol 17, No 3 (June 29, 2026): A prognostic nomogram based on log odds of positive lymph nodes to predict survival in gastric cancer patients with neoadjuvant chemotherapy: a large population-based cohort study and external validation Vol 17, No 3 (June 29, 2026): Rising prevalence of venous thromboembolism in gastrointestinal cancers: a nationwide analysis of 205 million hospitalizations, 2016–2022 Vol 17, No 3 (June 29, 2026): Comparison of preoperative urinary Titin levels and serum Titin levels in patients with gastrointestinal malignancy Vol 17, No 3 (June 29, 2026): Independent prognostic value of tumor deposits in stage III colorectal cancer: a large-scale systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): SOX18 knockdown inhibits colorectal cancer metastasis and angiogenesis through regulation of SAPK/JNK and PI3K/AKT/mTOR signaling pathways Vol 17, No 3 (June 29, 2026): Nursing-led enhanced recovery bundled care in colorectal cancer surgery: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Association of the global inflammatory-nutritional index (GINI) with time to next treatment and overall survival in patients with metastatic colorectal cancer receiving third-line therapy: a real-world retrospective study Vol 17, No 3 (June 29, 2026): Paeoniflorin inhibits colorectal cancer stem cell properties via regulating LINC01711/KMT2D/KLF7 axis Vol 17, No 3 (June 29, 2026): Development of a multivariable prediction model for tumor response and treatment tolerance based on body composition dynamics in rectal cancer undergoing neoadjuvant chemoradiotherapy Vol 17, No 3 (June 29, 2026): Younger age at colorectal cancer diagnosis in hereditary gastrointestinal cancer predisposition syndromes and Lynch syndrome: a nationwide analysis Vol 17, No 3 (June 29, 2026): Integrating network pharmacology, molecular docking, and experimental verification to investigate the mechanism of baicalein in colorectal cancer Vol 17, No 3 (June 29, 2026): Deep learning model based on MRI-derived microvascular network simulation parameters for noninvasive assessment of lymphovascular invasion in rectal cancer patients Vol 17, No 3 (June 29, 2026): Identification of telomere-related genes in the progression of colon adenocarcinoma: a bioinformatics analysis Vol 17, No 3 (June 29, 2026): Colorectal cancer survival in patients without curative measures: a retrospective cohort study Vol 17, No 3 (June 29, 2026): Association between preoperative aspartate aminotransferase-to-platelet ratio index and prognosis in colorectal liver metastases: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Transanal drainage tube versus diverting stoma for reducing anastomotic leakage after rectal cancer surgery: a systematic review and meta-analysis Vol 17, No 3 (June 29, 2026): Identification and preliminary examination of prognostic genes linked to calcium metabolism in colorectal cancer Vol 17, No 3 (June 29, 2026): Clinicopathological and molecular profiling of sporadic synchronous multiple primary colorectal cancers: focus on microsatellite instability status Vol 17, No 3 (June 29, 2026): Single-cell transcriptomics reveals the prognostic and immune infiltration significance of FOLFOX-bevacizumab treatment and lysine crotonylation characteristics in colon cancer Vol 17, No 3 (June 29, 2026): Prognostic and therapeutic significance of microscopic tumor focus in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study Vol 17, No 3 (June 29, 2026): Sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs as a potential approach for advanced hepatocellular carcinoma with portal vein tumor thrombus: a prospective study Vol 17, No 3 (June 29, 2026): A retrospective study on the outcomes of yttrium-90 radiation segmentectomy with resin microspheres compared to microwave ablation for early primary hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): The impact of adjuvant chemotherapy on overall survival and cancer-specific survival in patients with extrahepatic cholangiocarcinoma across different age groups: a population-based study Vol 17, No 3 (June 29, 2026): Mining and experimental validation of machine learning-based immune-related diagnostic biomarkers for hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): The role of number-of-excitations (NEX) for the usability of free-breathing acquired diffusion-derived ‘vessel density’ (DDVD) and slow diffusion coefficient (SDC) maps in separating liver cysts, hemangiomas, and solid masses with a focus on small lesions Vol 17, No 3 (June 29, 2026): Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): A nomogram‑based diagnostic prediction model for differentiating mucinous cystic neoplasms from simple hepatic cysts in patients with hepatic cystic lesions Vol 17, No 3 (June 29, 2026): Global burden landscape (1990–2021) of gallbladder and biliary tract cancer attributable to high body mass index in older adults and a projection to 2050 Vol 17, No 3 (June 29, 2026): Real-world feasibility and safety of neoadjuvant FOLFIRINOX in pancreatic ductal adenocarcinoma: a retrospective single-center study Vol 17, No 3 (June 29, 2026): A single-cell and machine learning framework identifies CAFs-associated signatures linking stromal heterogeneity to immune regulation in pancreatic cancer Vol 17, No 3 (June 29, 2026): Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study Vol 17, No 3 (June 29, 2026): Hepatocellular carcinoma metastasis to salivary glands: a systematic review of diagnostic challenges and survival outcomes Vol 17, No 3 (June 29, 2026): Deciphering the tubulin code: roles and mechanisms of microtubule post-translational modifications in gastrointestinal tumors: a narrative review Vol 17, No 3 (June 29, 2026): From metabolic dysregulation to malignancy: the presence of ZPR1 in gastrointestinal and hepatopancreatobiliary malignancies Vol 17, No 3 (June 29, 2026): A case report of diffuse large B-cell lymphoma and gastric signet ring cell adenocarcinoma in the same anatomic site: a clinical and management conundrum Vol 17, No 3 (June 29, 2026): Solid pseudopapillary neoplasm of the pancreas with postoperative multiple liver metastases in an older woman: a case report Vol 17, No 3 (June 29, 2026): Patterns of KRAS, NRAS, and BRAF mutations in colorectal cancer in Chile: a 3-year real-world evidence [2019–2021]—a brief report Vol 17, No 3 (June 29, 2026): Th1–2 immune balance revisited: refining prognostic immune signatures in colorectal cancer Vol 17, No 3 (June 29, 2026): Interpreting ctDNA dynamics in gastrointestinal stromal tumor (GIST) therapy—timing may be key Vol 17, No 3 (June 29, 2026): Revisiting prognostic biomarkers in gastrointestinal stromal tumor: the potential role of ETV1 polymorphisms Vol 17, No 3 (June 29, 2026): Pancreatic ductal adenocarcinoma and edema: reassessing cachexia markers Vol 17, No 3 (June 29, 2026): Preoperative resting heart rate and colorectal cancer mortality: a robust association, but causality remains unestablished Vol 17, No 3 (June 29, 2026): Predicting adherence of imatinib in gastrointestinal stromal tumor—rise of the machines! Vol 17, No 3 (June 29, 2026): Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges Vol 17, No 3 (June 29, 2026): Defining the role of endoscopic resection for esophageal gastrointestinal stromal tumors Vol 17, No 3 (June 29, 2026): Is the time of ethanol injection over?—has endoscopic ultrasonography-guided radiofrequency ablation become the preferred approach for small pancreatic neuroendocrine tumors? Vol 17, No 3 (June 29, 2026): Comparison of nomograms and predictive tools in gastrointestinal stromal tumor Vol 17, No 3 (June 29, 2026): Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia Vol 17, No 3 (June 29, 2026): Association between surgical timing and postoperative outcome in patients with residual esophageal cancer after neoadjuvant chemoradiotherapy Vol 17, No 3 (June 29, 2026): T-helper 1 and 2 cell densities, and mesenteric cytokine levels, are prognostic markers in colorectal cancer Vol 17, No 3 (June 29, 2026): Endoscopic resection for esophageal gastrointestinal stromal tumor: feasibility and oncologic limits Vol 17, No 3 (June 29, 2026): ESOPEC: targeting micro-metastatic disease combined with local control Vol 17, No 3 (June 29, 2026): Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Challenges identified from trends in mortality among patients with gastrointestinal cancer in the United States Vol 17, No 3 (June 29, 2026): A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations Vol 17, No 3 (June 29, 2026): From prediction to judgment: what a five-variable nomogram teaches us about hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Shifting from static to dynamic: the prognostic value of the surgical stress response in hepatocellular carcinoma Vol 17, No 3 (June 29, 2026): Ranking targeted therapies in advanced pancreatic adenocarcinoma: insights from a network meta-analysis Vol 17, No 3 (June 29, 2026): A hub for an herb: is STAT3 blockade at the epicenter of toosendanin-induced NCOA4-dependent ferritinophagy and ferroptosis in cancer cells? Vol 17, No 3 (June 29, 2026): Retraction: Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor Vol 17, No 3 (June 29, 2026): |
ASO Author Reflections: Who Gets the Rose? Insight Into How Breast Surgical Oncology Fellowship Program Directors Screen Applicants and Form Their Final Rank List
Sat, 11 Jul 2026 00:00:00 -0700 27th Annual Meeting of the American Society of Breast Surgeons Take Home Messages and Scientific Impact: The Verdict is in—We Moved the Needle Sat, 11 Jul 2026 00:00:00 -0700 Detection is Not Benefit: Sentinel Lymph Node Biopsy Omission in Invasive Lobular Carcinoma Sat, 11 Jul 2026 00:00:00 -0700 Variation in Surgical Management of Stage IV Breast Cancer: Local/Institutional and Regional Geographic Considerations Sat, 11 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Practice Patterns and Overall Survival for Octogenarians with Triple-Negative Breast Cancer Treated at Accredited Cancer Centers in the United States Fri, 10 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Does the Lymph Node Dissection during Esophagectomy Impact the Long-term Prognosis for Complete Responders After Neoadjuvant Therapy? A Meta-analysis Fri, 10 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study Fri, 10 Jul 2026 00:00:00 -0700 ASO Author Reflections: Rethinking Surgical Timing Benchmarks in Upfront Breast Cancer Surgery Fri, 10 Jul 2026 00:00:00 -0700 Practice Patterns and Overall Survival for Octogenarians with Triple Negative Breast Cancer Treated at Accredited Cancer Centers in the USA Fri, 10 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Impact of Next-Generation Sequencing on Surgical Decision-Making in Branch-Duct IPMN Thu, 09 Jul 2026 00:00:00 -0700 ASO Author Reflections: Expanding the Role of Targeted Axillary Dissection in Patients with Higher Nodal Burden After Neoadjuvant Systemic Therapy Thu, 09 Jul 2026 00:00:00 -0700 ASO Author Reflections: Baseline Liver Function and Long-Term Outcomes After Resection for Biliary Tract Cancer Thu, 09 Jul 2026 00:00:00 -0700 Applicant Selection and Ranking in Breast Surgical Oncology Fellowships: A National Survey of Program Leadership Thu, 09 Jul 2026 00:00:00 -0700 Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study Thu, 09 Jul 2026 00:00:00 -0700 Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma Thu, 09 Jul 2026 00:00:00 -0700 A Systematic Review and Meta-Analysis of Surgical Feasibility and Outcomes Following Neoadjuvant Immune Checkpoint Inhibition in Resectable Stage III and IV Melanoma Thu, 09 Jul 2026 00:00:00 -0700 ASO Visual Abstract: In Situ Anterior Approach to Dissect the Superior Mesenteric Artery in Minimally Invasive Pancreaticoduodenectomy: Step-by-Step Technique and Video Wed, 08 Jul 2026 00:00:00 -0700 ASO Visual Abstract: High-Volume Anesthesiologist and Surgeon Teams are Associated with Lower Operating Room Charges for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Wed, 08 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Long-Term Oncological Outcomes After Laparoscopic Resection and Thermal Ablation of Colorectal Liver Metastases Within a Parenchyma-Sparing Strategy Wed, 08 Jul 2026 00:00:00 -0700 The Dual Face of PD-L1 in Perioperative EGFR-Mutated Lung Cancer—Promise, Paradox, and the Path Forward Wed, 08 Jul 2026 00:00:00 -0700 ASO Author Reflections: Laparoscopy as a Dynamic Window into Occult Peritoneal Metastasis in Gastric Cancer Wed, 08 Jul 2026 00:00:00 -0700 ASO Author Reflections: Can Immunochemotherapy Redefine Neoadjuvant Treatment for Node-Positive Esophageal Squamous Cell Carcinoma? Wed, 08 Jul 2026 00:00:00 -0700 Nodal Pathologic Response After Neoadjuvant Systemic Therapy in Clinically Advanced Node-Positive (cN2 and cN3) Breast Cancer Wed, 08 Jul 2026 00:00:00 -0700 Lymphovascular Invasion in SOUND-Eligible Breast Cancer: Implications for Occult Axillary Nodal Metastasis Wed, 08 Jul 2026 00:00:00 -0700 Impact of Total and Positive Lymph Node Count on Recurrence in Young Women with Node-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy Wed, 08 Jul 2026 00:00:00 -0700 Taking Leave During Breast Surgical Oncology Fellowship: A National Evaluation of Policy and Practice Wed, 08 Jul 2026 00:00:00 -0700 Preoperative Nutritional Risk Defines Treatment Tolerance and Guides Adjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma Wed, 08 Jul 2026 00:00:00 -0700 The Impact of Surgery and Survival Prediction on Patients with Locally Advanced Gastric-type Endocervical Adenocarcinoma: A Population-Based Cohort Study Wed, 08 Jul 2026 00:00:00 -0700 Role of Sentinel Node Surgery in Identifying Candidates for Adjuvant CDK4/6 Inhibitors: Implications of Choosing Wisely and ASCO Omission Criteria Wed, 08 Jul 2026 00:00:00 -0700 The American Society of Breast Surgeons Official Proceedings, Volume XXVII 2026 Annual Meeting Scientific Session Abstracts Wed, 08 Jul 2026 00:00:00 -0700 Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis Wed, 08 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast—Rates of Nodal Involvement in Clinically Node-Negative Patients and Impact on Recurrence in a Single-Institution Analysis Tue, 07 Jul 2026 00:00:00 -0700 ASO Author Reflections: The Role of Lymphovascular Invasion in Early-Stage Breast Cancer Identified After the Omission of Sentinel Lymph Node Biopsy Tue, 07 Jul 2026 00:00:00 -0700 Letter to Editor of Annals of Surgical Oncology Concerning “The Impact of Diagnostic Laparoscopy on Upstaging Patients with Siewert II and III Gastroesophageal Junction (GEJ) Cancer” Tue, 07 Jul 2026 00:00:00 -0700 Resection of Primary Lung Tumors in Patients with Stage IV EGFR-Mutant Lung Adenocarcinoma before Progression under First-Line TKI Treatment and Its Impact on Prognosis Tue, 07 Jul 2026 00:00:00 -0700 The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas Tue, 07 Jul 2026 00:00:00 -0700 Surgical Safety after Preoperative Chemotherapy for Perihilar Cholangiocarcinoma: Multi-Institutional Propensity-Matched Analysis Tue, 07 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Imaging Overestimates the Local Extent of Breast Tumor After Neoadjuvant Chemotherapy Mon, 06 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis Mon, 06 Jul 2026 00:00:00 -0700 ASO Author Reflections: Reconsidering Surgical Indications for Clinical T4 Non-Small Cell Lung Cancer in the TNM 9th Edition Era Mon, 06 Jul 2026 00:00:00 -0700 ASO Visual Abstract: Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma Mon, 06 Jul 2026 00:00:00 -0700 Low Abundance of Cytotoxic Natural Killer Cells in Peritoneal Metastasis from Appendiceal Adenocarcinoma Suggests Tumor Immune Escape Mon, 06 Jul 2026 00:00:00 -0700 ASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4/6 Inhibition Mon, 06 Jul 2026 00:00:00 -0700 Expanding Eligibility for Targeted Axillary Dissection Mon, 06 Jul 2026 00:00:00 -0700 ASO Author Reflections: Atypical Breast Lesions on Core Needle Biopsy: Defining a Low-Risk Population to Guide Selective Surgical Excision Mon, 06 Jul 2026 00:00:00 -0700 ASO Author Reflections: Examined Lymph Node Stations as a Practical Metric for Adequate Lymphadenectomy in Pathological T1–2 Esophageal Squamous Cell Carcinoma Mon, 06 Jul 2026 00:00:00 -0700 Streamlining the Abstract Selection Process for the American Society of Breast Surgeons’ Annual Meeting by Utilizing Large Language Models Mon, 06 Jul 2026 00:00:00 -0700 Axillary Recurrence and Survival After Omission of Axillary Lymph Node Dissection in Patients with Breast Cancer and Micrometastases or Isolated Tumor Cells in the Sentinel Node: A Danish National Register Study Mon, 06 Jul 2026 00:00:00 -0700 Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis Mon, 06 Jul 2026 00:00:00 -0700 Functional Outcomes for Breast Cancer Survivors Following an Intense Resistance Training Program Based on Surgical Management of the Breast and Axilla Mon, 06 Jul 2026 00:00:00 -0700 |
||
|
| |||
|
Rapid Evaluation of Artificial Intelligence Technology Used for Ambient Dictation in Primary Care: Comparing the Quality of Documentation of Artificial Intelligence–Generated and Human-Produced Clinical Notes
Annals of Internal Medicine, Volume 179, Issue 6, Page 765-772, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness of Nonpharmacologic Treatments for Chronic Low Back Pain Annals of Internal Medicine, Volume 179, Issue 6, Page 773-784, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Low-Volume Polyethylene Glycol for Bowel Preparation in Hospitalized Adults Annals of Internal Medicine, Volume 179, Issue 6, Page 785-793, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans Annals of Internal Medicine, Volume 179, Issue 6, Page 794-803, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Twenty-Three–Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer Annals of Internal Medicine, Volume 179, Issue 6, Page 804-811, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study Annals of Internal Medicine, Volume 179, Issue 6, Page 812-822, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine Annals of Internal Medicine, Volume 179, Issue 6, Page 823-834, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2) Annals of Internal Medicine, Volume 179, Issue 6, Page 842-856, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 How Would You Manage This Patient With Iron Deficiency Anemia? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 6, Page 857-867, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Core Performance Measures for Migraine Headache: A Review by the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 6, Page 835-838, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reforming 340B to Promote Program Integrity and Better Serve Vulnerable Populations: An American College of Physicians Policy Brief Annals of Internal Medicine, Volume 179, Issue 6, Page 839-841, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 “Never More Than 15 Feet From the Respirator”: Housestaff Research During the 1955 Boston Polio Epidemic Annals of Internal Medicine, Volume 179, Issue 6, Page 868-873, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Integrating Planetary Health in Health Guidelines (GRADE Guidance 46) Annals of Internal Medicine, Volume 179, Issue 6, Page 874-884, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Importance of the Childhood Immunization Schedule for Internal Medicine Annals of Internal Medicine, Volume 179, Issue 6, Page 885-888, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Reframing Social Drivers of Health in Patient Quality and Safety Annals of Internal Medicine, Volume 179, Issue 6, Page 889-891, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Automatic Tenure-Clock Extensions as a Safeguard Against Defunding Annals of Internal Medicine, Volume 179, Issue 6, Page 892-894, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 What FDA Clearance Does, and Does Not, Mean for Artificial Intelligence Annals of Internal Medicine, Volume 179, Issue 6, Page 895-897, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Redefining Documentation Quality in the Age of Ambient Artificial Intelligence Scribes Annals of Internal Medicine, Volume 179, Issue 6, Page 898-899, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Incorporating Planetary Health Into Clinical Guideline Decisions Annals of Internal Medicine, Volume 179, Issue 6, Page 900-901, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 A Kite Without a String Annals of Internal Medicine, Volume 179, Issue 6, Page 902, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Cleo Annals of Internal Medicine, Volume 179, Issue 6, Page 903-904, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 All the Way Down Annals of Internal Medicine, Volume 179, Issue 6, Page 905-906, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Risk-Guided Antihypertensive Treatment Eligibility in Older Adults Under Updated Hypertension Guidelines Annals of Internal Medicine, Volume 179, Issue 6, Page 908-911, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Amputation Rates Among Opioid-Related Hospitalizations in the United States, 2016 to 2022 Annals of Internal Medicine, Volume 179, Issue 6, Page 911-914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 The Effect of 4:3 Intermittent Fasting on Weight Loss at 12 Months Annals of Internal Medicine, Volume 179, Issue 6, Page 915-916, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 Dollars Needed to Pay per Early-Detected Colorectal Cancer Case in Stool-Based Screening Annals of Internal Medicine, Volume 179, Issue 6, Page 914, June 2026. <br/> Fri, 17 Apr 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.
Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.
4 ovarian cancer candidates to watch: GSK, Allarity and more Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’ As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
New biotech cAMPfield emerges with $180M to reshape IBD treatment Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
Mirum, Incyte bolster case for approval in rare bone disease despite mid-stage miss While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.
Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3 Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.
Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026 Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis Eradivir Doses First Influenza Patient With EV25 in Bangladesh Study Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management |
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3 The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
Compass’ psilocybin depression drug works for the long haul New data from a Phase 3 trial will further support a rolling submission for Compass Pathways’ psilocybin treatment COMP360. Patients who saw a clinically meaningful benefit on depression severity maintained response through week 26.
BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy.
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.
Vistagen in freefall as social anxiety drug fails Phase 3 Despite the late-stage fail, Vistagen will nevertheless continue to push its drug candidate forward and meet with the FDA to align on a potential registrational path.
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.
4 ovarian cancer candidates to watch: GSK, Allarity and more Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor “What This Means” Segment Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis |
From sequence to scale: Gene editing’s new era in biologics manufacturing
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
Amgen continues to defend Tavneos as global regulatory pressure mounts Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3 The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
Compass’ psilocybin depression drug works for the long haul New data from a Phase 3 trial will further support a rolling submission for Compass Pathways’ psilocybin treatment COMP360. Patients who saw a clinically meaningful benefit on depression severity maintained response through week 26.
BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy.
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.
5 molecular glues that could stick—and the companies stuck in Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome Astellas to Spotlight New Research for Geographic Atrophy at ASRS 2026 Annual Meeting VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026 |
|
|
| |||
|
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:02 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:02 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:02 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:02 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:02 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:02 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:02 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:02 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:02 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:02 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:02 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:02 -0700
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:02 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:02 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
|
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries.
CA Cancer J Clin. 2026 Jul-Aug;76(4):e70090. doi: 10.3322/caac.70090. Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Jul 9;395(2):151-161. doi: 10.1056/NEJMoa2518990. Yue D, Huang M, Song P, Chen Y, Li B, Fu J, Guo J, Cheng C, Chen Q, Xu S, Liu H, Lv F, Hu J, Jiang K, Mao W, Shen B, Ye F, Li J, Zhang X, Guo S, Yu B, Zhu Y, Wu M, Zheng W, Chen F, He Z, Bai Y, Xin H, Chen K, Mao N, Zhang Y, Wang B, Zhang L, Chen X, Mei X, Miao L, Wang R, Li G, Yao J, Zhao J, Chen C, Liu J, Wei L, Yan X, Jin B, Liu X, Liu Z, Tian H, Xing W, Yang L, Ge D, Li X, Li S, Song Y, Zang A, Zhang D, Zhuang W, Liu Z, Yuan X, Fu T, Shen Z, Zhang X, Cao Q, Zhao L, Mao L, Ding L, Lu Y, Wang C; ELEVATE Study Group [Podiatric risk screening in patients with type 2 diabetes in Antananarivo]. Pan Afr Med J. 2017 Jul 20;27:213. doi: 10.11604/pamj.2017.27.213.11311. eCollection 2017. Raharinavalona SA, Ramalanjaona HR, Andrianera N, Patrick Rakotomalala AD, Ramahandridona G Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. N Engl J Med. 2026 Jul 9;395(2):138-150. doi: 10.1056/NEJMoa2512275. Miller JL, van Santen HM, Phillips SA, Hamilton J, Aberle J, Sathyapalan T, Mohamed Z, McCormack SE, Shoemaker AH, Kelsey MM, Ghalib L, Stalla G, Thaker VV, Habiby R, Ode KL, Wabitsch M, Dattani M, Abuzzahab MJ, Abdullatif H, Morgan R, Stefater-Richards M, Aroda VR, Friedrich C, Han JC, Ono H, Nagasaki K, Tanaka T, Isojima T, Arima H, Scimia C, Yuan G, Müller HL, Roth CL; TRANSCEND Trial Group Type 2 Diabetes in Morocco: Toward a Precision Diabetology, from Pathogenesis to Treatment. Ann Afr Med. 2026 Mar 1;25(2):297-303. doi: 10.4103/aam.aam_87_25. Epub 2025 Jul 23. Guerboub AA, Issouani J, Lakssir I, Srifi H, Riznat M, Malad M, Asfour M, Tadlaoui A, Errahali Y Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026 Jul 8;394:e372161. doi: 10.1136/bmj-2026-372161. Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia. Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10703-4. Ochi Y, Liew-Littorin M, Nannya Y, Bengtzen S, Piauger B, Deneberg S, Jädersten M, Lazarevic V, Cammenga J, Robelius A, Wennström L, Ölander E, Kasahara S, Hiramoto N, Kanemura N, Sezaki N, Sakurada M, Iwasaki M, Kanda J, Ueda Y, Yoshihara S, Erkers T, Struyf N, Watanabe Y, Motomura M, Nakagawa MM, Saiki R, Fukushima H, Okazaki K, Morimoto S, Yoda A, Okuda R, Komatsu S, Xie G, Österroos A, Kon A, Zhao L, Shiraishi Y, Ishikawa T, Miyano S, Katayama K, Imoto S, Matsuda S, Takaori-Kondo A, Aburatani H, Suzuki HI, Kallioniemi O, Juliusson G, Höglund M, Lehmann S, Ogawa S A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci. Nat Genet. 2013 Aug;45(8):907-11. doi: 10.1038/ng.2686. Epub 2013 Jun 30. Hinds DA, McMahon G, Kiefer AK, Do CB, Eriksson N, Evans DM, St Pourcain B, Ring SM, Mountain JL, Francke U, Davey-Smith G, Timpson NJ, Tung JY Nutrition Therapy in Critically Ill Adults. N Engl J Med. 2026 Jul 9;395(2):162-174. doi: 10.1056/NEJMra2506111. Patel JJ, McClave SA Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol. 2026 Jul 8:S2213-8587(26)00122-1. doi: 10.1016/S2213-8587(26)00122-1. Dobbie LJ, Tolvanen L, Alves D, Baker JL, Bez NS, Birney S, Bogl LH, Brown A, Bullo M, Clare K, Duncan EL, Govers E, Mooney V, Mulrooney H, Mercado DO, O'Malley G, Oppert JM, Pillinger T, Remijnse W, Shuttlewood E, Wakolbinger M, Woodward E, Yumuk VD, Hassapidou M, Ciudin A, McGowan B Itch in Organs Beyond the Skin. Curr Allergy Asthma Rep. 2020 Jun 19;20(9):49. doi: 10.1007/s11882-020-00947-z. Golpanian RS, Smith P, Yosipovitch G Autonomous biomedical research with an artificial intelligence agent. Science. 2026 Jul 9:eadz4351. doi: 10.1126/science.adz4351. Huang K, Zhang S, Wang H, Qu Y, Lu Y, Li R, Roohani Y, Qiu L, Cao S, Li G, Zhang J, Yin D, Wierenga R, Kavi D, Liu S, She T, Marwaha S, Carter JN, Zhou X, Wheeler MT, Bernstein JA, Wang M, He P, Zhou J, Snyder MP, Cong L, Regev A, Leskovec J Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis. 2026 Jul 1:S1473-3099(26)00295-1. doi: 10.1016/S1473-3099(26)00295-1. GBD 2023 TB HIV Collaborators Diet-microbiome synergy underlies obesity-associated immunotherapy efficacy. Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10750-x. Desharnais L, Swaby A, Messaoudene M, Doré S, Yu MW, Fiset B, Breton V, Ponce M, Hu Y, Wilson L, Sorin M, Wang Y, Dewar K, Pollak M, Elkrief A, Routy B, Walsh LA, Quail DF Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues. Science. 2026 Jul 9;393(6807):188-194. doi: 10.1126/science.aef5391. Epub 2026 Jul 9. Ojeda S, Wang M, Baek K, Bourgeois W, Sommerschield A, Yue H, Metivier RJ, Karagiannis P, Levitz TS, Xiong Y, Donovan KA, Armstrong SA, Fischer ES C1q and immunoglobulins mediate activity-dependent synapse loss in the adult brain. Science. 2026 Jul 9;393(6807):eadv1219. doi: 10.1126/science.adv1219. Epub 2026 Jul 9. Crowley G, Kim M, O'Neill N, Turkes E, Ghasemi F, Giudice L, De Schepper S, Tan BJY, Maffei B, S S Ferreira L, Rebejac J, Rueda-Carrasco J, Toneva M, Fajardo JC, Ge JZ, Yang ZG, Korhonen P, Muckett P, Bennett D, Paoletti C, Sow TTM, Posner DA, Sierksma A, Sokolova D, Konstantellos V, Ali L, Movahedi K, MacAskill AF, Tybulewicz VLJ, Malm T, Lignani G, Clatworthy MR, Hong S Different modes of engagement with the nucleosome acidic patch yield distinct functional outcomes. Nucleic Acids Res. 2026 Jul 3;54(13):gkag693. doi: 10.1093/nar/gkag693. Chakraborty U, Saccone EC, Cruz-Becerra G, Khan LF, Arslanovic N, Aguilar R, Gloor SL, Hunt SR, Folkwein HJ, Husby NL, Maier KE, Marunde MR, Schomburg NK, Vaidya A, Cowles MW, Venters BJ, Kassavetis G, Sun ZW, Kadonaga JT, Armache JP, Keogh MC, Tyler JK In vivo feasibility study of humanoid robots in surgery. Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10796-x. Liang Z, Thareja N, Zhang P, Joyce C, Atar S, Richter F, Jacobsen G, Liu S, Broderick R, Yip M Targeting of CH25H to boost p62-dependent autophagic degradation of α-synuclein in cell and mouse models of Parkinson's disease. Sci Transl Med. 2026 Jul 8;18(857):eadv7705. doi: 10.1126/scitranslmed.adv7705. Epub 2026 Jul 8. Zhang X, Han R, Zhang W, Xu S, Wang Y, Wang M, Du R, Liu Y, Zhang L, Wang C, Zhang K, Hu G, Xu H, Cao L, Lu M Aneuploidy selects for the acquisition of driver genes in breast cancer. Nature. 2026 Jul 8. doi: 10.1038/s41586-026-10752-9. Al-Zahrani KN, Langille ER, Nurtanto J, Obersterescu A, Teng K, Lowden C, Dessapt J, Chiu CH, Caldwell LV, Cook DP, Pérez-Castro MA, Berman JM, Tsai R, Bahcheli AT, Mbamalu G, Wu S, Narimatsu M, Lopes AG, Fotiadou I, Chan K, Zhang L, Bang KWA, Parsons MJ, Mourao L, Temel EI, McCulla L, Sravya P, Zhang L, Sajjakulnukit P, Lyssiotis CA, Borowsky AD, Scheele CLGJ, Wahl DR, Jackson HW, Stewart KS, Fuchs E, Egan SE, Pujana MA, Reimand J, Wrana JL, Schramek D |
||